Date of event

Washington, District of Columbia United States

Continuing Education Credits
Add to Calendar 2020-03-21 13:00:00 2020-03-22 16:15:00 AASLD / EASL NAFLD and NASH Clinical Endpoints Conference This endpoints meeting will present evidence-based knowledge on NAFLD’s potential triggers, various stages of disease, biomarkers for diagnosis, disease severity, treatment and translation of effectiveness of this information to clinical practice. Washington, DC United States AASLD America/New_York public

Registration and conference abstract submitter to open Wednesday, November 20 at 9:00 am ET.

Course Description / Needs Statement

Leading experts in nonalcoholic fatty liver disease research and therapy explore bench to bedside therapeutic discovery and patient management approaches at this exciting conference. Faculty present recent evidence on NAFLD’s potential triggers, disease stages, biomarkers for diagnosis and disease severity, and treatments; how to effectively translate knowledge to clinical practice; and strategies to create effective multidisciplinary teams to optimize disease outcomes.

Program Chairs

  • Ariel E. Feldstein, MD
  • Manal F. Abdelmalek, MD, MPH, FAASLD
  • Philip N. Newsome, MD, PhD
  • Elisabetta Bugianesi MD, PhD


  • The Westin Crystal City
    1800 Jefferson Davis Hwy
    Arlington, VA 22202

Continuing Education

Continuing Medical Education will not be provided at this conference.

Related Conference Note

Consider registering for AASLD’s Emerging Topic Conference, which will take place at the same location on March 20-21, 2020.

Travel Note

US residents: Please review the Real ID Act regarding boarding federally regulated commercial aircrafts. Depending on your state of residence, you may need to provide a second form of identification at the airport.

Schedule Note

Breakfast is served at 7:00 am ET both days.

Session I: Endpoints in Pre-Clinical Development
Moderators: Ariel E. Feldstein, MD and Anne Mae Diehl, MD, FAASLD

  • 1:00 pm – 1:10 pm
    Ariel E. Feldstein, MD and Elisabetta Bugianesi, MD
  • 1:10 pm – 1:30 pm
    The Power of Single Cell Analysis to Enable Discovery of Novel Targets for NASH
    Jiandie Lin, PhD
  • 1:30 pm – 1:50 pm
    Human Model Systems of NAFLD/NASH
    Takanori Takebe, MD
  • 1:50 pm – 2:10 pm
    Novel Murine Models to Assess Anti-Inflammatory and Anti-Fibrotic Therapies
    Michael Karin, PhD
  • 2:10 pm – 2:30 pm
    What’s the Connection Between Preclinical Models and Patients Included in Clinical Trials?
    Anne Mae Diehl, MD, FAASLD
  • 2:30 pm – 2:50 pm
    Panel Discussion / Q&A
  • 2:50 pm – 3:20 pm

Session II: Endpoints in Early Phase Clinical Trials
Moderators: Manal F. Abdelmalek, MD, MPH, FAASLD and Quentin M. Anstee, MBBS, PhD, FRCP

  • 3:20 pm – 3:40 pm
    Selecting the Right Objectives in Early Phase Clinical Studies
    Julia Brosnan
  • 3:40 pm – 4:00 pm
    Patient Heterogeneity and Potential Biases in Early Phase Clinical Studies
    Manal F. Abdelmalek, MD, MPH, FAASLD
  • 4:00 pm – 4:20 pm
    Strengths and Limitations of Serum/Imaging Biomarkers as Surrogate Endpoints
    Rohit Loomba, MD
  • 4:20 pm – 4:40 pm
    Novel Omics Based Approaches as Surrogates in Early Phase Studies
    Jose M. Mato, PhD
  • 4:40 pm – 5:00 pm
    Evaluating Therapies in Pediatric NASH: Meaningful Endpoints
    Miriam B. Vos, MD, MSPH
  • 5:00 pm – 5:30 pm
    Panel Discussion / Q&A

Session III: Endpoints in Late Stage Clinical Development (Non-cirrhotic NASH)
Moderators: Philip N. Newsome, MD, PhD and Naga P. Chalasani, MD, PhD

  • 8:00 am – 8:20 am
    The Current Status Quo: What’s Right About Late-Stage Endpoints, But What Should Change?
    Vlad Ratziu, MD
  • 8:20 am – 8:40 am
    Perspective of Regulatory Authorities (FDA) on Endpoints
    Lara Dimick-Santos, MD
  • 8:40 am – 9:00 am
    Perspective of Regulatory Authorities (EMA) on Endpoints
  • 9:00 am – 9:20 am
    The Payer Perspective on Endpoints for Drug Approval
  • 9:20 am – 9:40 am
    Panel Discussion / Q&A
  • 9:40 am – 10:10 am

Session IV: Applications of Endpoints in Different Settings
Moderators: Vlad Ratziu, MD and Judith M. Ertle, MD

  • 10:10 am – 10:30 am
    Endpoints in Compensated and Decompensated Cirrhosis
    Naga P. Chalasani, MD, PhD
  • 10:30 am – 10:50 am
    When Endpoints Are Not Met in Cirrhosis Trials: Lessons Learned
    Quentin M. Anstee, MBBS, PhD, FRCP
  • 10:50 am – 11:10 am
    Evaluating Use of NASH Therapies Post-transplant: Bridging the Gap
    Patrizia Burra, MD, PhD
  • 11:10 am – 11:45 am
    Panel Discussion / Q&A
  • 11:45 am – 12:45 pm

Session V: Clinical Trial Considerations
Moderators: Elisabetta Bugianesi, MD and Quentin M. Anstee, MBBS, PhD, FRCP

  • 12:45 pm – 1:05 pm
    Standardizing Approach to Lifestyle: Meaningful Endpoints
    Miriam Lazo, MD
  • 1:05 pm – 1:25 pm
    Do We Need a Placebo?: Use of Historical Cohorts
    Judith M. Ertle, MD
  • 1:25 pm – 1:45 pm
    Combination Therapy and Adaptive Trial Designs: Lessons Learned from the IBD Field
  • 1:45 pm – 2:15 pm
    Q&A/ Panel Discussion
  • 2:15 pm – 2:45 pm

Session VI: Endpoints and Other Challenges in Clinical Practice
Moderators: Manal F. Abdelmalek, MD, MPH, FAASLD and Philip N. Newsome, MD, PhD

  • 2:45 pm – 3:05 pm
    Meaningful Endpoints in Clinical Practice
    Philip N. Newsome, MD, PhD
  • 3:05 pm – 3:25 pm
    Management of Anti-metabolic Medications in Clinical Trials: What to Do to Avoid Bias and Confounding
  • 3:25 pm – 3:45 pm
    Patient Related Outcomes in NASH
    Helena Cortez Pinto, MD, PhD
  • 3:45 pm – 4:05 pm
    Pathways for Referral to Therapy in Clinical Practice
    Elisabetta Bugianesi, MD
  • 4:05 pm – 4:15 pm
    Conference Summary and Wrap-Up
    Manal F. Abdelmalek, MD, MPH, FAASLD and Philip N. Newsome, MD, PhD
  • 4:15 pm

US Residents: Review the Real ID Act regarding boarding federally regulated commercial aircrafts. Depending on your state of residence, you may need to provide a second form of identification at the airport.


The Westin Crystal City
1800 Jefferson Davis Hwy
Arlington, VA 22202

Make your Online Reservations
Phone: 703-486-1111

If you are calling to make a reservation, let the hotel representative know you are attending the AASLD meeting.


Single/Double $169 per night plus tax

Cancellation Policy

All hotel room reservations must be cancelled within 48 hours of scheduled arrival date to receive a refund.


  • Ronald Reagan National Airport (DCA)
  • Washington Dulles International Airport (IAD)

Ground Transportation

Shuttle Services
Complimentary shuttle services to the hotel are provided from 5:30 am – 11:00 pm daily to and from the DCA airport. If using this option, stand by the hotel shuttle pick up outside of the airport.

There is no shuttle service from the IAD airport.

From DCA the taxi fare estimation is $12 (one way) and from IAD is $65. Both are estimations for one-way fares.

Metro / Subway / Public Transportation
The nearest WMATA metro station is the Crystal City Metro Station (both Blue and Yellow lines). The metro station is .1 miles from the Westin Crystal City Hotel. The estimated metro fare from DCA is $2.25 and from IAD is $6. Both reflect one-way fares.


Self-parking at the hotel is $16 hourly and $34 daily. Valet parking fee is $40 daily.

Press Policies and Guidelines

The American Association for the Study of Liver Diseases provides credentialed media with complimentary press registration. Below is information on eligibility and the credentialing process.

Press Eligibility

Journalists, and contributing freelancers, employed by a recognized news organization are eligible to apply for press registration. To be eligible for press registration, media in all categories must be directly involved in the creation of news content for organizations that meet these criteria:

  • Publish original editorial news coverage in a regular news section
  • Have complete editorial freedom from advertisers, funders and/or sponsors
  • If sponsored, the outlet has multiple sponsors (no single-sponsored publications)
  • Advertisers, sponsors, paid editorial and other funding sources are clearly identified


Bloggers will receive press credentials on a case-by-case basis. Please include a link to recent liver disease, hepatology or health care science coverage with your registration for credentials. Finally, all blogs must demonstrate the dissemination of original, editorial news coverage and editorial freedom from advertisers and/or sponsors (single-sponsored blogs will not receive credentials; blogs with advertising must have multiple advertisers clearly identified).


Photographers, videographers, and/or other members of the multimedia team accompanying credentialed news outlets may register as media and provide a link to recent coverage from their team. Further credentialing may be required during the approval process.

NOTE: AASLD has the right to inspect the credentials of anyone registering as media and reserves the right to deny media registration to anyone who does not meet the above guidelines. AASLD also has the right to limit the number of media registrants from any one media outlet to ensure ample space for all media.

Ineligible Registrants

The following individuals are not eligible for press registration or access to the Newsroom:

  • Individuals who receive exhibitor passes
  • Publishers or a publications’ advertising, marketing, public relations, sales, circulation, or any other non-editorial function representatives
  • Industry/exhibitor press officers and their public relations consultants
  • Financial or business analysts
  • Educational program developers (including CME writers and editors)
  • Trade media management personnel
  • Editors, writers, and scientific advisory board members for journals that do not have editorial news sections
  • Companies or organizations producing publications, videos, and/or other electronic media intended for internal use, marketing, advertising, financial analysis, or public relations purposes
  • Media who produce a communications vehicle that is sponsored by a single organization or whose revenue for the publication or issue of a publication depends solely on coverage of 2020 AASLD/EASL NAFLD and NASH Clinical Endpoints Conference
  • Media who produce a communications vehicle that uses the AASLD’s name or logo, or the Emerging Topic Conference name/logo to imply endorsement from AASLD

NOTE: AASLD prohibits the development of CME content based on information presented at its meetings. CME writers and editors, and those writers and editors working on behalf of organizations that have written CME based on AASLD meetings, are not eligible for press passes.

Prohibited Activities

  • Sales, marketing or representing a company for the purposes of obtaining advertising, subscriptions, selling photography/video production, or other products or services from any registrant or exhibitor
  • Misrepresentation of role or activities to obtain media registration
  • Developing or assisting in the development of continuing medical education programs
  • Soliciting presenters and/or attendees for inclusion in CME programs
  • Publishing or posting presentation slides, live streams of meeting presentations, or sharing copyrighted meeting materials without written permission.

Video/Audio Recording

Television and video crews are required to check in immediately with AASLD staff each day.

Television and video crews must be wearing press badges. Shooting schedules must be provided to AASLD staff in advance of the meeting.

Permission of the speaker and moderator must be obtained by the journalist before recording or photographing presentations. Artificial light and flash photography cannot be used during presentations. Handheld audio recorders and still cameras are acceptable, assuming that intellectual property copyrights are respected.

Under no circumstances may presentations be rebroadcasted.

Any images from the meeting should be credited to: 2020 AASLD/EASL NAFLD and NASH Clinical Endpoints Conference.

Use of Insignias and Logos

Insignias and logos of the AASLD, this meeting or AASLD Foundation are proprietary marks. Use of these in any fashion, by any entity, for any purpose, is prohibited without the written permission of AASLD. The use of insignias, logos and images that mislead the intended audience to believe that a piece or production is coming from the AASLD is strictly prohibited and will result in the denial of press credentials for future meetings.

Dedicated Websites and Newsletters

If you intend to present coverage of this meeting in a dedicated website or newsletter, please include the following disclaimer at the top of your piece: This information is brought to you by [insert organization name] and is not sponsored by, nor a part of, the Association for the Study of Liver Diseases or 2020 AASLD/EASL NAFLD and NASH Clinical Endpoints Conference. Additionally, you may not use the AASLD’s logo or name to imply affiliation.

AASLD reserves the right to request promotional activities violating this policy be edited or removed. Failure to comply with these guidelines may result in loss of press credentials for future meetings.

Applying for Press Credentials

Requests for press credentials should be sent to and must be sent by Friday, March 13, 2020. Onsite press registration cannot be accommodated. When sending your request for credentials, include two of the following:

  • Bylined news coverage
  • Copy of official press credentials
  • Assignment letter
  • Two recent posts about liver disease and/or health care (for bloggers)